Status:
COMPLETED
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the ...
Eligibility Criteria
Inclusion
- Patients with asthma, either well-controlled on a regular therapy with a combination of long-acting beta-agonists and inhaled corticosteroids or symptomatic on therapy with inhaled corticosteroids alone.
Exclusion
- Any other significant lung disease other than asthma
- Any disease that might put patients at risk if they participate in the study
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT00252863
Start Date
December 1 2004
End Date
May 1 2006
Last Update
March 17 2009
Active Locations (169)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stuttgart, Baden-Wurttemberg, Germany
2
Research Site
München, Bavaria, Germany
3
Research Site
Cottbus, Brandenburg, Germany
4
Research Site
Hamburg, Hamburg, Germany